ArticleNature communications2019
Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy.
Erratum issuedAbstract read
In one paragraph
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 42 papers.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- Cell death and immune escape in the tumor microenvironment: associated mechanisms, opportunities and challenges.Apoptosis : an international journal on programmed cell death · 2026Review
- Thimerosal Inhibits Tumor Malignant Progression through Direct Action and Enhancing the Efficacy of PD-1-Based Immunotherapy.Oncology research · 2026Article
- Nonsense-mediated mRNA decay inhibits TRAF6-dependent anti-tumor immunity in colorectal cancer.Cell reports. Medicine · 2025Article
- Integrative analysis reveals prognostic value of cuproptosis and copper hemostasis related genes in immunotherapy for non-small cell lung cancer.NPJ precision oncology · 2025Article
- The role of PD-L1 gene silencing on growth, migration, and apoptosis in oral squamous carcinoma cell line HN-5.Annals of medicine and surgery (2012) · 2025Article
- STAT3/TGFBI signaling promotes the temozolomide resistance of glioblastoma through upregulating glycolysis by inducing cellular senescence.Cancer cell international · 2025Article
- Development of a streamlined NGS-based TCGA classification scheme for gastric cancer and its implications for personalized therapy.Journal of gastrointestinal oncology · 2024Article
- Microbiome bacterial influencers of host immunity and response to immunotherapy.Cell reports. Medicine · 2024Review
- Respiratory complex I regulates dendritic cell maturation in explant model of human tumor immune microenvironment.Journal for immunotherapy of cancer · 2024Article
- Hepsin promotes breast tumor growth signaling via the TGFβ-EGFR axis.Molecular oncology · 2024Article
- Cell Death Pathway Regulation by Functional Nanomedicines for Robust Antitumor Immunity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Current Advances and Future Strategies for BCL-2 Inhibitors: Potent Weapons against Cancers.Cancers · 2023Review
- Comprehensive prediction of immune microenvironment and hot and cold tumor differentiation in cutaneous melanoma based on necroptosis-related lncRNA.Scientific reports · 2023Article
- Review
- [Cuproptosis-related immune gene signature predicts clinical benefits from anti-PD-1/PD-L1 therapy in non-small-cell lung cancer.Immunologic research · 2023Article
- Novel Anti-Cancer Products Targeting AMPK: Natural Herbal Medicine against Breast Cancer.Molecules (Basel, Switzerland) · 2023Review
- Breast cancer patient-derived explant cultures recapitulateFrontiers in oncology · 2023Article
- Metformin in therapeutic applications in human diseases: its mechanism of action and clinical study.Molecular biomedicine · 2022Review
- Patient stratification based on urea cycle metabolism for exploration of combination immunotherapy in colon cancer.BMC cancer · 2022Article
- Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer.Nature communications · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
27 authors.
Heidi M HaikalaCancer Cell Circuitry Laboratory, Research Programs Unit/Translational Cancer Biology and Medicum, University of Helsinki, P.O. Box 63, Street address: Haartmaninkatu 8, 00014, Helsinki, Finland.ORCID http://orcid.org/0000-0002-8465-8568
Johanna M AnttilaCancer Cell Circuitry Laboratory, Research Programs Unit/Translational Cancer Biology and Medicum, University of Helsinki, P.O. Box 63, Street address: Haartmaninkatu 8, 00014, Helsinki, Finland.
Elsa MarquesCancer Cell Circuitry Laboratory, Research Programs Unit/Translational Cancer Biology and Medicum, University of Helsinki, P.O. Box 63, Street address: Haartmaninkatu 8, 00014, Helsinki, Finland.
Tiina RaatikainenCancer Cell Circuitry Laboratory, Research Programs Unit/Translational Cancer Biology and Medicum, University of Helsinki, P.O. Box 63, Street address: Haartmaninkatu 8, 00014, Helsinki, Finland.
Mette IlanderHematology Research Unit Helsinki, Department of Clinical Chemistry and Hematology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Haartmaninkatu 8, 00290, Helsinki, Finland.
Henna HakanenHematology Research Unit Helsinki, Department of Clinical Chemistry and Hematology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Haartmaninkatu 8, 00290, Helsinki, Finland.
Hanna Ala-HongistoCancer Cell Circuitry Laboratory, Research Programs Unit/Translational Cancer Biology and Medicum, University of Helsinki, P.O. Box 63, Street address: Haartmaninkatu 8, 00014, Helsinki, Finland.
Mariel SaveliusCancer Cell Circuitry Laboratory, Research Programs Unit/Translational Cancer Biology and Medicum, University of Helsinki, P.O. Box 63, Street address: Haartmaninkatu 8, 00014, Helsinki, Finland.
Diego BalboaResearch Programs Unit/Molecular Neurology, Biomedicum Stem Cell Center, University of Helsinki, Haartmaninkatu 8, 00290, Helsinki, Finland.ORCID http://orcid.org/0000-0002-4784-5452
Bjoern Von EyssLeibniz Institute of Age Research, Fritz Lipmann Institute e.V, Beutenbergstraße 11, 07745, Jena, Germany.ORCID http://orcid.org/0000-0002-4731-6841
Vilja EskelinenCancer Cell Circuitry Laboratory, Research Programs Unit/Translational Cancer Biology and Medicum, University of Helsinki, P.O. Box 63, Street address: Haartmaninkatu 8, 00014, Helsinki, Finland.
Pauliina MunneCancer Cell Circuitry Laboratory, Research Programs Unit/Translational Cancer Biology and Medicum, University of Helsinki, P.O. Box 63, Street address: Haartmaninkatu 8, 00014, Helsinki, Finland.
Anni I NieminenDepartment of Biosciences and Institute of Biotechnology, University of Helsinki, Viikinkaari 5, 00790, Helsinki, Finland.
Timo OtonkoskiResearch Programs Unit/Molecular Neurology, Biomedicum Stem Cell Center, University of Helsinki, Haartmaninkatu 8, 00290, Helsinki, Finland.ORCID http://orcid.org/0000-0001-9190-2496
Julia SchülerOncotest GmbH, (Now part of Charles River Laboratories Inc, 251 Ballardvale St, Wilmington, MA 01887, USA), Freiburg, Germany.
Teemu D LaajalaInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Tukholmankatu 3, 00290, Helsinki, Finland.
Tero AittokallioInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Tukholmankatu 3, 00290, Helsinki, Finland.ORCID http://orcid.org/0000-0002-0886-9769
Harri SihtoResearch Programs Unit / Translational Cancer Biology & Medicum, University of Helsinki, P.O. Box 63 (Street address: Haartmaninkatu 8), 00290, Helsinki, Finland.ORCID http://orcid.org/0000-0001-5265-5509
Johanna MattsonDepartment of Oncology, University of Helsinki and Helsinki University Hospital, Haartmaninkatu 4, 00290, Helsinki, Finland.
Päivi HeikkiläDepartment of Pathology, University of Helsinki and Helsinki University Hospital, Haartmaninkatu 3, 00290, Helsinki, Finland.
Marjut LeideniusBreast Surgery Unit, Helsinki University Hospital, Kasarmikatu 11-13, 00290, Helsinki, Finland.
Heikki JoensuuResearch Programs Unit / Translational Cancer Biology & Medicum, University of Helsinki, P.O. Box 63 (Street address: Haartmaninkatu 8), 00290, Helsinki, Finland.
Satu MustjokiHematology Research Unit Helsinki, Department of Clinical Chemistry and Hematology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Haartmaninkatu 8, 00290, Helsinki, Finland.ORCID http://orcid.org/0000-0002-0816-8241
Panu KovanenDepartment of Pathology, HUSLAB and Haartman Institute, University of Helsinki and Helsinki University Hospital, Haartmaninkatu 3, 00290, Helsinki, Finland.
Martin EilersTheodor Boveri Institute and Comprehensive Cancer Center Mainfranken, Biocenter, University of Würzburg, Am Hubland, D-970074, Germany.ORCID http://orcid.org/0000-0002-0376-6533
Joel D LeversonOncology Development, AbbVie, Inc., 1 N Waukegan Road, North Chicago, IL, 60064, USA.
Juha KlefströmCancer Cell Circuitry Laboratory, Research Programs Unit/Translational Cancer Biology and Medicum, University of Helsinki, P.O. Box 63, Street address: Haartmaninkatu 8, 00014, Helsinki, Finland. Juha.Klefstrom@helsinki.fi.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elevated MYC expression sensitizes tumor cells to apoptosis but the therapeutic potential of this mechanism remains unclear. We find, in a model of MYC-driven breast cancer, that pharmacological activation of AMPK strongly synergizes with BCL-2/BCL-X
Indexed as
ImmunotherapyAniline CompoundsAnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsApoptosisbcl-X ProteinBreast NeoplasmsBridged Bicyclo Compounds, HeterocyclicCD8-Positive T-LymphocytesCell Line, TumorCell SurvivalClustered Regularly Interspaced Short Palindromic RepeatsDrug CombinationsFemaleAniline CompoundsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsatezolizumabBcl2l1 protein, mouseBCL2 protein, humanbcl-X ProteinBridged Bicyclo Compounds, HeterocyclicDrug CombinationsMetforminnavitoclaxProto-Oncogene Proteins c-bcl-2Sulfonamidesvenetoclax
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.